Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Loureirin B
Cat. No.:
0225LY-1055
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR.
Size:
Add to basket
Product Overview
Description:
Loureirin B mitigates TGF-β1-induced fibrosis and prevents the proliferation of scar fibroblasts by modulating the balance of TIMPs and MMPs to downregulate fibrosis-related markers, a process likely involving the TGF-β1/Smad2/3 signaling axis.
Synonym:
119425-90-0; 1-(4-hydroxyphenyl)-3-(2,4,6-trimethoxyphenyl)propan-1-one; 1-Propanone, 1-(4-hydroxyphenyl)-3-(2,4,6-trimethoxyphenyl)-; Propan-1-one, 1-(4-hydroxyphenyl)-3-(2,4,6-trimethoxyphenyl)-; 4'-hydroxy-2,4,6-trimethoxydihydrochalcone
CAS No.:
119425-90-0
Compound CID:
189670
Formula:
C18H20O5
Formula Weight:
316.35
Specification
Targets&IC50:
PAI1: 26.10 μM
Relative Density:
1.177 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Loureirin B can be used in regenerative medicine to study the promotion of wound healing and hair follicle stem cell activation.
Library Information
Target:
JNK; ERK; Potassium channel; PAI-1
Receptor:
ERK; JNK; PAI-1; Potassium channel
Pathways:
Metabolism; MAPK; Membrane transporter/Ion channel
Plate Number:
AOCL-14
Plate Location:
e10
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
150 mg/mL; 474.16 mM
